Lilly bags Trulicity FDA approval for reducing CV risk in type 2 diabetes patients
Trulicity FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug Administration (FDA) for Trulicity (dulaglutide) to reduce ... Read More
Lilly to build $470m pharma manufacturing plant in North Carolina
US pharma giant Eli Lilly and Company (Lilly) will build a new pharma manufacturing plant in North Carolina with an investment of more than $470 ... Read More
Lilly to acquire US dermatology drug company Dermira for $1.1bn
Lilly acquisition of Dermira : US pharma giant Eli Lilly and Company (Lilly) has agreed to acquire California-based dermatology drug company Dermira for about $1.1 ... Read More
Lilly launches LIBRETTO-431 clinical trial for selpercatinib in NSCLC
Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) ... Read More
Lilly bags Reyvow FDA approval for acute treatment of migraine
Reyvow FDA approval : Eli Lilly and Company (Lilly) has bagged approval from the US Food and Drug Administration (FDA) for Reyvow (lasmiditan) for the ... Read More
Eli Lilly’s Emgality gets FDA green light for migraine prevention
Eli Lilly and Company has secured approval from the US Food and Drug Administration (FDA) for its migraine drug Emgality (galcanezumab-gnlm) as a preventative therapy ... Read More
Lilly completes acquisition of immuno-oncology firm Armo BioSciences
Strategic Expansion in Cancer Treatment: Eli Lilly and Company (Lilly), a leading US pharmaceutical firm, has finalized its acquisition of Armo BioSciences, a California-based immuno-oncology ... Read More
Eli Lilly’s Cyramza fails to improve survival in gastric cancer trial despite meeting initial goal
In a recent announcement, Eli Lilly and Company disclosed that its phase 3 RAINFALL trial of the drug Cyramza (ramucirumab) for the treatment of HER2-negative ... Read More
FDA approves Eli Lilly’s Verzenio for metastatic breast cancer treatment
Eli Lilly and Company (Lilly) has announced receiving U.S. Food and Drug Administration (FDA) approval for Verzenio (abemaciclib), to treat patients with metastatic breast cancer ... Read More
Lilly’s breast cancer drug abemaciclib shows promising results in phase 3 trial
Indianapolis-based pharmaceutical giant Lilly has announced positive outcomes from its phase 3 clinical trial, MONARCH 2, involving its innovative breast cancer treatment, abemaciclib, in combination ... Read More